TITLE

Pulegone-induced damages in mice ovarian tissue correlates with CYP19 gene expression

AUTHOR(S)
Souldouzi, R.; Razi, M.; Shalizar, A.; Amani, S.
PUB. DATE
June 2014
SOURCE
Iranian Journal of Reproductive Medicine;Jun2014 Supplement, Vol. 12, p100
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Introduction: Pulegone is a naturally occurring organic compound in variety of plants that is widely used for flavoring foods, drinks, and dental products. However, there are several reports indicating its cytotoxic effect on various cell types. The CYP19 is an enzyme catalysing the conversion of androgens into oestrogens. Therefore, present study was conducted in order to uncover the effect of ±pulegune on CYP19 mRNA expression and its impact on follicular growth in mice model. Materials and Methods: Twenty four mature female mice were divided into control-sham (received 0.5 mL normal saline, orally) and test groups including; 25mg/kg, 50mg/kg and 100mg/kg pulegone-treated groups. The mRNA level of CYP19 was assessed by semiquantitative-PCR. Total follicle and atretic follicles distribution per ovary and serum level of estradiol were evaluated. Results: Pulegone reduced CYP19 expression in a dose dependent manner. Pulegone-received animals exhibited significantly (p<0.05) lower follicle distribution and remarkably (p<0.05) higher number of atretic follicles versus control-sham groups. Depending on dose, the serum level of estradiol decreased in pulegone-treated animals. Conclusion: In conclusion, our data showed that pulegone exerts its pathological impact by decreasing oestrogen synthesis via down-regulating CYP19 expression. Ultimately, pathologically altered oestrogen synthesis provokes follicular atresia.
ACCESSION #
96841735

 

Related Articles

  • p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Ferrandina, G; Fagotti, A; Salerno, M G; Natali, P G; Mottolese, M; Maneschi, F; Pasqua, A De; Benedetti-Panici, P; Mancuso, S; Scambia, G // British Journal of Cancer;10/15/99, Vol. 81 Issue 4, p733 

    The aim of this study was to assess the association of p53 status with primary cytoreduction, response to chemotherapy and outcome in stage III-IV primary ovarian cancer patients. Immunohistochemical analysis of p53 was performed on formalin-fixed, paraffin-embedded specimens from 168 primary...

  • Molecular Characterization of Corona Radiata Cells.  // Fertility Weekly;8/13/2012, p7 

    The article reports on a study which determines the molecular characterization of corona radiata cells (CRCs) in patients with diminished ovarian reserve (DOR) through gene expression profiling in France. The researchers have aimed to identify the deregulated genes that are involved in the...

  • Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Mirza, Asra; Wu, Qun; Wang, Luquan; McClanahan, Terri; Bishop, W Robert; Gheyas, Ferdous; Ding, Wei; Hutchins, Beth; Hockenberry, Tish; Kirschmeier, Paul; Greene, Jonathan R; Liu, Suxing // Oncogene;6/5/2003, Vol. 22 Issue 23, p3645 

    The temporal gene expression profile during the entire process of apoptosis and cell cycle progression in response to p53 in human ovarian cancer cells was explored with cDNA microarrays representing 33?615 individual human genes. A total of 1501 genes (4.4%) were found to respond to p53...

  • Eutopic endometrium and peritoneal, ovarian and colorectal endometriotic tissues express a different profile of Nectin-1, -3, -4 and nectin-like molecule 2. Ballester, Marcos; Gonin, Julie; Rodenas, Anita; Bernaudin, Jean-François; Rouzier, Roman; Coutant, Charles; Daraï, Emile // Human Reproduction;Nov2012, Vol. 27 Issue 11, p3179 

    STUDY QUESTION How is the expression of nectins and nectin-like molecules (Necls) detected by immunostaining altered by endometriosis? SUMMARY ANSWER Our results suggest that Nectin-1, -3, -4 and Necl-2 may contribute to the pathogenesis of endometriosis. Immunostaining of nectins and Necls...

  • Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer. Ferrandina, Gabriella; Mey, Valentina; Nannizzi, Sara; Ricciardi, Simona; Petrillo, Marco; Ferlini, Cristiano; Danesi, Romano; Scambia, Giovanni; Del Tacca, Mario // Cancer Chemotherapy & Pharmacology;Mar2010, Vol. 65 Issue 4, p679 

    Gemcitabine (2′,2′-difluorodeoxycytidine) (GEM) is one of the most actively investigated drugs in ovarian cancer. Many molecular mechanisms have been proposed to be involved in GEM sensitivity/resistance including the equilibrative nucleoside transporter-1 (hENT1), the concentrative...

  • TP53 status determines clinical significance of ERBB2 expression in ovarian cancer. Kupryjańczyk, J.; M&acedil;dry, R.; Plisiecka-Hałasa, J.; Bar, J.; Kraszewska, E.; Ziólkowska, I.; Timorek, A.; Stelmachów, J.; Emerich, J.; J&eogony;dryka, M.; Płu&zgrave;ańska, A.; Rzepka-Górska, I.; Urbański, K.; Zieliński, J.; Markowska, J. // British Journal of Cancer;11/29/2004, Vol. 91 Issue 11, p1916 

    ERBB2 expression has been found in 19 to 44%of ovarian carcinomas; however, its predictive value has not been demonstrated, and trastuzumab has not found clinical application in ovarian cancer patients. We evaluated clinical significance of ERBB2 expression in relation to TP53 accumulation in...

  • Establishment of Cisplatin-Resistant Ovarian Yolk Sac Tumor Cells and Investigation of the Mechanism of Cisplatin Resistance Using This Cell Line. Shibata, Kiyosumi; Umezu, Tomokazu; Sakurai, Maiko; Kajiyama, Hiroaki; Yamamoto, Eiko; Ino, Kazuhiko; Nawa, Akihiro; Kikkawa, Fumitaka // Gynecologic & Obstetric Investigation;Mar2011, Vol. 71 Issue 2, p104 

    Background: Cisplatin is used as a key drug for ovarian yolk sac tumor (YST), but relapse may occur. Details of the molecular mechanism responsible for cisplatin resistance remain unclear. Methods: We established cisplatin-resistant ovarian YST cells (NOY1-CR) from parent NOY1. To characterize...

  • Expression of Angiopoietin-1, Angiopoietin-2, and Tie2 Genes in Normal Ovary with Corpus luteum and in Ovarian Cancer. Hata, Kohkichi; Udagawa, Jun; Fujiwaki, Ritsuto; Nakayama, Kentaro; Otani, Hiroki; Miyazaki, Kohji // Oncology;2002, Vol. 62 Issue 4, p340 

    Objective: The recent discovery of angiopoietin-1 (Ang1) and angiopoietin-2 (Ang2) has provided novel and important insights into the molecular mechanisms of blood vessel formation. Ang1 and Ang2 bind with similar affinity to the endothelial cell tyrosine kinase receptor Tie2. Our purpose was to...

  • An Outlook on Ovarian Cancer and Borderline Ovarian Tumors: Focus on Genomic and Proteomic Findings. Tinelli, Andrea; Vergara, Daniele; Martignago, Roberta; Leo, Giuseppe; Pisanó, Maurizio; Malvasi, Antonio // Current Genomics;Jun2009, Vol. 10 Issue 4, p240 

    Among the gynaecological malignancies, ovarian cancer is one of the neoplastic forms with the poorest prognosis and with the bad overall and disease-free survival rates than other gynaecological cancers. Ovarian tumors can be classified on the basis of the cells of origin in epithelial, stromal...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics